Shots:
- The OLYMPIA long-term extension study assessed Nemluvio in 508 pts with prurigo nodularis up to 4yrs., which were enrolled from the P-II or P-III (OLYMPIA 1 & 2) trials
- Interim analysis at Wk. 100 showed sustained improvement, with over 90% achieving ≥4-point itch reduction & 70% being itch-free or nearly itch-free per Peak-Pruritus Numerical Rating Scale; ≥80% achieved 76–100% healing of pruriginous lesions, & ~75% attained clearance or near-clearance of skin nodules based on the IGA score
- Additionally, ARCADIA long-term extension study data, presented at RAD 2025, which demonstrated sustained improvements in atopic dermatitis symptoms for ~2yrs.
Ref: Galderma | Image: Galderma| Press Release
Related News:- NextCure Signs a ~$745M Licensing Agreement with Simcere Zaiming for SIM0505
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
